Hyman B. Muss

841 total papers · 46.5k total citations
556 papers, 29.6k citations indexed

About

Hyman B. Muss is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hyman B. Muss has authored 556 papers receiving a total of 29.6k indexed citations (citations by other indexed papers that have themselves been cited), including 338 papers in Oncology, 155 papers in Cancer Research and 130 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hyman B. Muss's work include Breast Cancer Treatment Studies (141 papers), Cancer Treatment and Pharmacology (108 papers) and Frailty in Older Adults (103 papers). Hyman B. Muss is often cited by papers focused on Breast Cancer Treatment Studies (141 papers), Cancer Treatment and Pharmacology (108 papers) and Frailty in Older Adults (103 papers). Hyman B. Muss collaborates with scholars based in United States, Israel and Canada. Hyman B. Muss's co-authors include Shlomit Strulov Shachar, Grant R. Williams, Donald A. Berry, Constance Cirrincione, Tomohiro F. Nishijima, Larry Norton, Allison M. Deal, Clifford A. Hudis, Kirsten A. Nyrop and Eric P. Winer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Hyman B. Muss

538 papers receiving 28.7k citations

Hit Papers

Improved Outcomes From Ad... 1994 2026 2004 2015 2003 2005 2013 2016 1994 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
    2003 921 citations I. Craig Henderson, Donald A. Berry et al. Journal of Clinical Oncology profile →
  2. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
    2005 817 citations Paul E. Goss, James N. Ingle et al. JNCI Journal of the National Cancer Institute profile →
  3. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
    2013 817 citations Kevin S. Hughes, Lauren A. Schnaper et al. Journal of Clinical Oncology profile →
  4. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review
    2016 788 citations Shlomit Strulov Shachar, Grant R. Williams et al. European Journal of Cancer profile →
  5. c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
    1994 779 citations Hyman B. Muss, Ann D. Thor et al. New England Journal of Medicine profile →
  6. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
    2004 731 citations Kevin S. Hughes, Lauren A. Schnaper et al. New England Journal of Medicine profile →
  7. Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
    2005 621 citations Hyman B. Muss, J.T. Thigpen et al. Journal of Clinical Oncology profile →
  8. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
    2006 517 citations Donald A. Berry, Constance Cirrincione et al. JAMA profile →
  9. Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
    2016 443 citations Hope S. Rugo, R. Bryan Rumble et al. Journal of Clinical Oncology profile →
  10. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
    2016 411 citations Paul E. Goss, James N. Ingle et al. New England Journal of Medicine profile →
  11. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer
    2016 401 citations Arti Hurria, Supriya G. Mohile et al. Journal of Clinical Oncology profile →
  12. Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum
    2012 317 citations Lee W. Jones, Hyman B. Muss et al. Journal of Clinical Oncology profile →
  13. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions
    2020 281 citations Mina S. Sedrak, Rachel A. Freedman et al. CA A Cancer Journal for Clinicians profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Hyman B. Muss 17.1k 9.3k 5.7k 4.4k 4.1k 556 29.6k
Clifford A. Hudis 23.5k 1.4× 14.1k 1.5× 6.9k 1.2× 1.7k 0.4× 868 0.2× 510 39.6k
Jeffrey A. Meyerhardt 16.2k 0.9× 3.9k 0.4× 4.2k 0.7× 5.0k 1.1× 938 0.2× 428 25.7k
Matti Aapro 10.6k 0.6× 2.1k 0.2× 4.0k 0.7× 3.9k 0.9× 1.9k 0.5× 489 22.3k
Dawn L. Hershman 12.6k 0.7× 3.5k 0.4× 3.8k 0.7× 1.8k 0.4× 474 0.1× 715 27.0k
Alfred I. Neugut 12.4k 0.7× 4.2k 0.4× 6.4k 1.1× 1.3k 0.3× 484 0.1× 674 31.1k
Hans Wildiers 7.5k 0.4× 3.4k 0.4× 3.2k 0.6× 1.7k 0.4× 2.6k 0.6× 389 14.5k
J.W.W. Coebergh 16.3k 1.0× 4.5k 0.5× 6.4k 1.1× 832 0.2× 587 0.1× 521 30.6k
Arti Hurria 9.5k 0.6× 2.4k 0.3× 4.9k 0.9× 4.5k 1.0× 7.4k 1.8× 322 20.1k
Michael Gnant 13.0k 0.8× 9.9k 1.1× 5.6k 1.0× 1.3k 0.3× 412 0.1× 552 37.8k
John R. Mackey 14.8k 0.9× 4.0k 0.4× 4.6k 0.8× 2.8k 0.6× 511 0.1× 335 24.5k

Countries citing papers authored by Hyman B. Muss

Since Specialization
Citations

This map shows the geographic impact of Hyman B. Muss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyman B. Muss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyman B. Muss more than expected).

Fields of papers citing papers by Hyman B. Muss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyman B. Muss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyman B. Muss. The network helps show where Hyman B. Muss may publish in the future.

Co-authorship network of co-authors of Hyman B. Muss

This figure shows the co-authorship network connecting the top 25 collaborators of Hyman B. Muss. A scholar is included among the top collaborators of Hyman B. Muss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hyman B. Muss. Hyman B. Muss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David S. Alberts Breakdown of academic impact, for papers by G. Schubert Breakdown of academic impact, for papers by Jordi Rello Breakdown of academic impact, for papers by Lyle L. Moldawer Breakdown of academic impact, for papers by Marie‐Geneviève Mattéi Breakdown of academic impact, for papers by Özgür Kişi Breakdown of academic impact, for papers by Hexing Li Breakdown of academic impact, for papers by Irwin J. Kopin
Rankless by CCL
2026